secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001213900-24-079165
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics reports two ovarian cancer patients exceed one year on stenoparib therapy
--------------------------------------------------------------------------------

- Two patients in Phase 2 trial for advanced recurrent ovarian cancer have exceeded one year on stenoparib.
- Patients pre-screened using DRP companion diagnostic; show durable clinical benefit in heavily pre-treated population.
- One confirmed complete response and long-term disease stability observed.
- CEO notes extending life by 52 weeks is noteworthy for heavily pre-treated patients.
- Company planning next phase of development, accelerating path toward regulatory approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024079165/0001213900-24-079165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024079165/ea021470501-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-079165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer